Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus

Clinical and Experimental Dermatology, 05/03/2012

The authors report a 32–year–old woman who developed TEN secondary to sulfasalazine, which was treated with infliximab. The infliximab treatment subsequently triggered erosive lichen planus (LP) involving the mouth and vulva. Clinicians should be aware that TNF–α antagonists can cause LP as a paradoxical complication of treatment.

Print Article Summary Cat 2 CME Report